Get the Stockscreener App
27.02
2.56%
-0.71
Bicara Therapeutics Inc stock is traded at $27.02, with a volume of 479.75K.
It is down -2.56% in the last 24 hours and up +5.38% over the past month.
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa.
See More
Previous Close:
$27.73
Open:
$27.73
24h Volume:
479.75K
Relative Volume:
0.72
Market Cap:
$1.78B
Revenue:
-
Net Income/Loss:
$-137.95M
P/E Ratio:
-10.71
EPS:
-2.5226
Net Cash Flow:
$-107.11M
1W Performance:
-2.67%
1M Performance:
+5.38%
6M Performance:
+61.41%
1Y Performance:
+126.49%
1-Day Range:
$26.68
$28.22
1-Week Range:
$26.68
$28.33
52-Week Range:
$9.57
$30.99
Bicara Therapeutics Inc Stock (BCAX) Company Profile
Name
Bicara Therapeutics Inc
Sector
Industry
Phone
617-468-4219
Address
116 HUNTINGTON AVENUE SUITE 703, BOSTON
Compare BCAX vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCAX
Bicara Therapeutics Inc
|
27.02 | 1.78B | 0 | -137.95M | -107.11M | -2.5226 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-25-26 | Initiated | BofA Securities | Buy |
| Jan-29-26 | Initiated | Citizens JMP | Mkt Perform |
| Jan-08-26 | Initiated | BTIG Research | Buy |
| Dec-18-25 | Initiated | Mizuho | Neutral |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| May-23-25 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Apr-17-25 | Initiated | Wells Fargo | Underweight |
| Feb-06-25 | Initiated | Wedbush | Outperform |
| Dec-06-24 | Initiated | H.C. Wainwright | Buy |
| Nov-05-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-08-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-08-24 | Initiated | Morgan Stanley | Overweight |
| Oct-08-24 | Initiated | Stifel | Buy |
| Oct-08-24 | Initiated | TD Cowen | Buy |
View All
Bicara Therapeutics Inc Stock (BCAX) Latest News
Bicara Therapeutics (BCAX) Corporate presentation Summary - Quartr
Bicara Therapeutics (BCAX) Proxy filing Summary - Quartr
Bicara Therapeutics (BCAX) Study update Summary - Quartr
Bicara Therapeutics (BCAX) Q1 2026 earnings summary - Quartr
Form 4 Bicara Therapeutics Inc For: 14 July By Investing.com - Investing.com South Africa
Bicara Therapeutics CEO Claire Mazumdar disposes of $284k in stock - Investing.com Nigeria
Bicara Therapeutics CEO Claire Mazumdar disposes of $284k in stock By Investing.com - Investing.com India
Form 4 Bicara Therapeutics Inc For: 14 July - Investing.com India
Bicara Therapeutics (BCAX) CEO exercises options and sells 10,000 shares under 10b5-1 plan - Stock Titan
Enterprise value to revenue forward of Bicara Therapeutics Inc. – NASDAQ:BCAX - TradingView
Extended Trial Data And Insider Sale Could Be A Game Changer For Bicara Therapeutics (BCAX) - Sahm
Bicara therapeutics president & COO sells $833k in stock By Investing.com - Investing.com India
Bicara Therapeutics CFO Hyep Ivan sells $807k in stock By Investing.com - Investing.com India
Form 144 Bicara Therapeutics Inc. For: 10 July By Investing.com - Investing.com Nigeria
Enterprise value to EBIT forward of Bicara Therapeutics Inc. – NASDAQ:BCAX - TradingView
Form 4 Bicara Therapeutics Inc For: 10 July By Investing.com - Investing.com South Africa
Bicara Therapeutics CFO Hyep Ivan sells $807k in stock - Investing.com
Bicara therapeutics president & COO sells $833k in stock - Investing.com
Bicara Therapeutics Insider Sold Shares Worth $833,129, According to a Recent SEC Filing - marketscreener.com
[Form 4] Bicara Therapeutics Inc. Insider Trading Activity - Stock Titan
Bicara Therapeutics (BCAX) COO exercises options, sells 28,750 shares under plan - Stock Titan
Price to sales forward of Bicara Therapeutics Inc. – BOATS:BCAX - TradingView
Price to book forward of Bicara Therapeutics Inc. – NASDAQ:BCAX - TradingView
Form 144 BICARA THERAPEUTICS INC. For: 8 July By Investing.com - Investing.com Nigeria
Form 144 Bicara Therapeutics Inc. For: 8 July By Investing.com - Investing.com Nigeria
BCAX (NASDAQ) insider sales: 50,000-share option exercise set for 07/08/2026 - Stock Titan
Sale notice: 28,750 shares disclosed by BCAX (NASDAQ: BCAX) - Stock Titan
BCAX (NASDAQ) affiliate files Rule 144; past sales of 9,200 shares noted - Stock Titan
Bicara Therapeutics (BCAX) Piper Sandler 37th Annual Healthcare Conference Summary - Quartr
Form 144 BICARA THERAPEUTICS INC. For: 7 July By Investing.com - Investing.com Nigeria
Bicara Therapeutics Inc stock hits all-time high at 29.92 USD - Investing.com Nigeria
Price to earnings forward of Bicara Therapeutics Inc. – NASDAQ:BCAX - TradingView
Enterprise value to EBITDA forward of Bicara Therapeutics Inc. – NASDAQ:BCAX - TradingView
BCAX Q1 2026 Earnings: Clinical-Stage Biotech Misses on EPS as Stock Edges HigherRevenue Report - dars.gov.et
Bicara Therapeutics Inc. Actuals & Estimates (NASDAQ:BCAX) - TradingView
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Bicara Therapeutics Inc Stock (BCAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Bicara Therapeutics Inc Stock (BCAX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mazumdar Claire | Chief Executive Officer |
Jul 10 '26 |
Sale |
28.42 |
10,000 |
284,198 |
362,152 |
| Cohlhepp Ryan | President and COO |
Jul 08 '26 |
Option Exercise |
3.79 |
18,750 |
71,059 |
210,391 |
| Cohlhepp Ryan | President and COO |
Jul 08 '26 |
Sale |
28.98 |
28,214 |
817,585 |
182,177 |
| Cohlhepp Ryan | President and COO |
Jul 09 '26 |
Sale |
29.00 |
536 |
15,544 |
181,641 |
| Hyep Ivan | Chief Financial Officer |
Jul 08 '26 |
Option Exercise |
3.79 |
12,500 |
47,372 |
157,855 |
| Hyep Ivan | Chief Financial Officer |
Jul 08 '26 |
Sale |
28.85 |
28,000 |
807,672 |
129,855 |
0.46%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):